Peptilogics
peptilogics.com
Actively hiring
Oncology Therapeutics
Drug Discovery
As featured in
Claim pageClaim
Follow
Overview
Connections
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$118.9M
5 rounds on record
Latest round
$78M
Venture round · Oct 2025 · 12 mo ago
Team
16
US Form 5500 (plan participants) · Dec 2025 · +14% in a year
Hiring now
1
open roles
Backers
2
AMR Action Fund, Riverfront Ventures
The money's age
Due for its next round
12 months since the last round · hiring slowed
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 16, 2025
Raised a round Venture round $78M · PRNewswire
Jul 12, 2022
New executive Peptilogics Promotes Nicholas Nystrom, Ph.D., to Chief Technology Officer · peptilogics.com
Apr 27, 2022
Partnership Peptilogics and Cerebras Systems Partner on AI Solutions to Advance the Future of Peptide Therapeutics · peptilogics.com
Apr 27, 2022
Certified Peptilogics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Trial of PLG0206 in Periprosthetic Joint Infection · peptilogics.com
Dec 15, 2020
Raised a round Venture round $35.8M · SEC Form D
Aug 18, 2017
Raised a round Venture round $4M · SEC Form D
May 2, 2017
Raised a round Venture round $754k · SEC Form D
Jan 8, 2016
Raised a round Venture round $417k · SEC Form D
2013
Founded
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Oct 2025 | $78M | — | PRNewswire |
| Venture round | Dec 2020 | $35.8M | — | SEC Form D |
| Venture round | Aug 2017 | $4M | — | SEC Form D |
| Venture round | May 2017 | $754k | — | SEC Form D |
| Venture round | Jan 2016 | $417k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Peptilogics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Jonathan SteckbeckExecutive Officer, DirectorSEC Form D
Sanjay KakkarExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Cloverleaf Bio is an early-stage therapeutics company developing a new class of engineered RNA therapeutics for cancer therapy. It hires…
Kriya is building durable medicines designed to replace chronic re-treatment with a single administration—therapeutic medicines that can…
CAMPfield Therapeutics is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor…
We are decoding the role of the extracellular matrix (ECM) in health and disease to discover new drug targets, biomarkers, and novel…
Alpheus is advancing a new therapeutic approach designed to improve outcomes while reducing treatment burden for patients and families.
Soricimed Biopharma is a clinical stage drug development company dedicated to novel trageted treatments for cancer.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
AMR Action FundVia a fund
Riverfront VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Former President of Depuy Synthes U.S. Joins Peptilogics Board
#top .av-special-heading.av-mmktiypu-699ad5d4b11a8bb90d014b38515c349b{ padding-bottom:10px; } body .av-special-heading.av-mmktiypu-699ad5d4b11a8bb90d014b38515c349b .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-mmktiypu-69
Read more
Report
Century Group Sets 2026 AGM to Approve Accounts, Board Slate and Share Mandate
Detailed price information for Abcellera Biologics Inc (ABCL-Q) from The Globe and Mail including charting and trades.
Read more
Report
Peptilogics Begins Pivotal Trial of First-Ever Drug Designed to Cure Medical Device-Related Infections
#top .av-special-heading.av-mmktiypu-b0d707846ebd600d97b636e2f789dc6f{ padding-bottom:10px; } body .av-special-heading.av-mmktiypu-b0d707846ebd600d97b636e2f789dc6f .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-mmktiypu-b0
Read more
Report
Report
Peptilogics: $78 Million Raised For Advancing Zaloganan Toward Pivotal Trial For Prosthetic Joint Infections
Peptilogics, a clinical-stage biotechnology company pioneering surgical therapeutics for medical device infections, has closed an oversubscribed $78 million Series B2 financing round. The funding round was led by Presight Capital, Thiel Bio, and Founders
Read more
Report
Peptilogics Raises $78 Million to Advance Zaloganan Into Pivotal Trial
#top .av-special-heading.av-li0vc12u-b8a5632e2951a3ec2838a76d717084fd{ padding-bottom:10px; } body .av-special-heading.av-li0vc12u-b8a5632e2951a3ec2838a76d717084fd .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-li0vc12u-b8
Read more
Report
Peptilogics Raises $78 Million to Advance Zaloganan Into Pivotal Trial
/PRNewswire/ -- Peptilogics, a clinical-stage biotechnology company developing transformative surgical therapeutics to effectively treat and prevent serious...
Read more
Report
Peptilogics Reports Positive 180-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI)
#top .av-special-heading.av-li0vc12u-c81d5a9b762f16c9f06a214cd19e7ca3{ padding-bottom:10px; } body .av-special-heading.av-li0vc12u-c81d5a9b762f16c9f06a214cd19e7ca3 .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-li0vc12u-c8
Read more
Report
Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI)
#top .av-special-heading.av-li0vc12u-d169c65c07911238f090972d5803b1aa{ padding-bottom:10px; } body .av-special-heading.av-li0vc12u-d169c65c07911238f090972d5803b1aa .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-li0vc12u-d1
Read more
Report
Peptilogics Completes Phase 1b Trial Enrollment and Will Present Interim Top-line Safety and Tolerability Data of PLG0206 in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection After a Total Knee Arthroplasty at ECCMID 2023
#top .av-special-heading.av-lehsq0k2-f8749283457b74a1f819d176a86275fc{ padding-bottom:10px; } body .av-special-heading.av-lehsq0k2-f8749283457b74a1f819d176a86275fc .av-special-heading-tag .heading-char{ font-size:25px; } .av-special-heading.av-lehsq0k2-f8
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Peptilogics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
2
Postings analysed
1
Stack modernity
53/100
Cloud & platforms
GCP
Practices & domains
Good Clinical Practice
Sign in to see how your skills match this stack
Sign In
People
Jonathan Steckbeck
Executive Officer, Director
Sanjay Kakkar
Executive Officer, Director
Stephan Dietrich
Director
Stefan Roever
Director
Catherine Mott
Director
Dietrich Stephan
Director
Hannes Holste
Director
Jason Camm
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
23/100
Hiring freeze
Open positions
1
0 opened / 2 closed in 30 days
Median time-to-fill
73 days
faster than 17% of the market
ATS activity
Every ~5 hours
11/03/2026
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Finance
67% ▼
Biotech
33% ▼
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Pittsburgh
Pittsburgh
United States
HQ
Pittsburgh
1 open roles 3 posted in 90 days 100% remote 10-50 est. staff
hires for Finance
2681 Sidney Street, Pittsburgh, PA 15203
Financials
Total raised
$118.9M
Latest round
Venture - Series Unknown
Funding rounds
5